Proteomic Analysis Reveals AMPKα ‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer
Cancer Science · 2026-11 · 117 (11) · 3086-3097
DOI: 10.1111/cas.70477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 13.07.2026. Verfasst von Masaki Shiota und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Ferroptosis, Prostatic Neoplasms, AMP-Activated Protein Kinases, Drug Resistance, Neoplasm. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Princess Takamatsu Cancer Research Fund.
Abstract (Originalsprache)
Metastatic prostate cancer often develops resistance to second‐generation androgen receptor pathway inhibitors (ARPIs) such as enzalutamide and darolutamide, limiting their long‐term efficacy. In this study, we applied the high‐precision absolute quantitative proteomics platform iMPAQT to comprehensively profile protein expression changes in multiple prostate cancer cell lines and their ARPI‐resistant derivatives. Our analysis revealed consistent dysregulation of ferroptosis suppressor pathway alongside elevated phosphorylation of AMPKα signaling in resistant cells. While antiandrogen treatment increased lipid peroxidation in parental cells, resistant cells adapted by upregulating key ferroptosis‐regulating proteins including FTH1 and GPX4, thereby evading ferroptosis. Functional assays demonstrated that the GPX4 inhibitor RSL3 selectively suppressed proliferation of resistant cells more potently than parental cells. Moreover, combination treatment with AMPKα inhibitors enhanced the anti‐proliferative effect of RSL3. These findings suggest that ferroptosis suppression is a critical mechanism underpinning resistance to ARPIs in prostate cancer. Targeting pathways involved in ferroptosis regulation in combination with AMPKα inhibitors holds promise for overcoming therapeutic resistance and improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Masaki Shiota, Tokiyoshi Tanegashima, Shigehiro Tsukahara, Masatoshi Eto
Förderung
- Princess Takamatsu Cancer Research Fund
Zitieren
APA
Shiota, M., Tanegashima, T., Hajime, T., Ushijima, M., Tsukahara, S., Nagakawa, S., Kobayashi, S., Matsumoto, T., & Eto, M. (2026). Proteomic Analysis Reveals AMPKα ‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer. Cancer Science, 117(11), 3086-3097. https://doi.org/10.1111/cas.70477
Vancouver
Shiota M, Tanegashima T, Hajime T, Ushijima M, Tsukahara S, Nagakawa S, et al. Proteomic Analysis Reveals AMPKα ‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer. Cancer Science. 2026;117(11):3086-3097. doi:10.1111/cas.70477
BibTeX
@article{Shiota2026,
author = {Shiota, Masaki and Tanegashima, Tokiyoshi and Hajime, Takahiko and Ushijima, Miho and Tsukahara, Shigehiro and Nagakawa, Shohei and Kobayashi, Satoshi and Matsumoto, Takashi and Eto, Masatoshi},
title = {Proteomic Analysis Reveals AMPKα ‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {11},
pages = {3086--3097},
doi = {10.1111/cas.70477}
}
EUVIMED